Drug Recall: CONGESTAID II Nasal Decongestant for Manufacturing Deviations
Ultra Seal Corporation is recalling CONGESTAID II Nasal Decongestant packets due to current Good Manufacturing Practice (cGMP) deviations. The voluntary nationwide recall affects 447,050 packets.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries mentioned in the source. The hazard is based on manufacturing process deviations without specific identified contamination, fitting the 'voluntary precautionary recalls' criterion.
Plain-English summary
Ultra Seal Corporation is recalling CONGESTAID II Nasal Decongestant (Phenylephrine HCl 5mg) 2-tablet packets due to current Good Manufacturing Practice (cGMP) deviations. The product was distributed by ZEE Medical Distributors, LLC and sold nationwide within the United States.
The recall was initiated due to cGMP deviations identified during manufacturing. The specific nature of these deviations is not detailed in the recall notice.
A total of 447,050 packets are affected. The recalled product includes Lot #AK9478 (expiration date 02/2022) and Lot #AK9799 (expiration date 09/2022). This recall was terminated on October 16, 2023.
Consumers who have purchased this product should stop using it. For further information or guidance on the recall, consumers may contact Ultra Seal Corporation or consult the FDA.
The recalled product
- Product
- CONGESTAID II Nasal Decongestant (Phenylephrine HCl 5mg) 2 tablet packets, Dist. by ZEE Medical Distributors, LLC Mason, OH 45040
- Manufacturer
- Ultra Seal Corporation
- Category
- Drug
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: AK9478
- Exp. Date 02/2022
- AK9799
- Exp. Date 09/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27